TY - JOUR
T1 - Ultraearly hematoma growth in active intracerebral hemorrhage
AU - Rodriguez-Luna, David
AU - Coscojuela, Pilar
AU - Rubiera, Marta
AU - Hill, Michael D.
AU - Dowlatshahi, Dar
AU - Aviv, Richard I.
AU - Silva, Yolanda
AU - Dzialowski, Imanuel
AU - Lum, Cheemun
AU - Czlonkowska, Anna
AU - Boulanger, Jean Martin
AU - Kase, Carlos S.
AU - Gubitz, Gord
AU - Bhatia, Rohit
AU - Padma, Vasantha
AU - Roy, Jayanta
AU - Tomasello, Alejandro
AU - Demchuk, Andrew M.
AU - Molina, Carlos A.
N1 - Publisher Copyright:
© 2016 American Academy of Neurology.
PY - 2016/7/26
Y1 - 2016/7/26
N2 - Objective: To determine the association of ultraearly hematoma growth (uHG) with the CT angiography (CTA) spot sign, hematoma expansion, and clinical outcomes in patients with acute intracerebral hemorrhage (ICH). Methods: We analyzed data from 231 patients enrolled in the multicenter Predicting Haematoma Growth and Outcome in Intracerebral Haemorrhage Using Contrast Bolus CT study. uHG was defined as baseline ICH volume/onset-to-CT time (mL/h). The spot sign was used as marker of active hemorrhage. Outcome parameters included significant hematoma expansion (>33% or >6 mL, primary outcome), rate of hematoma expansion, early neurologic deterioration, 90-day mortality, and poor outcome. Results: uHG was higher in spot sign patients (p < 0.001) and in patients scanned earlier (p < 0.001). Both uHG >4.7 mL/h (p 0.002) and the CTA spot sign (p 0.030) showed effects on rate of hematoma expansion but not its interaction (2-way analysis of variance, p 0.477). uHG >4.7 mL/h improved the sensitivity of the spot sign in the prediction of significant hematoma expansion (73.9% vs 46.4%), early neurologic deterioration (67.6% vs 35.3%), 90-day mortality (81.6% vs 44.9%), and poor outcome (72.8% vs 29.8%), respectively. uHG was independently related to significant hematoma expansion (odds ratio 1.06, 95% confidence interval 1.03-1.10) and clinical outcomes. Conclusions: uHG is a useful predictor of hematoma expansion and poor clinical outcomes in patients with acute ICH. The combination of high uHG and the spot sign is associated with a higher rate of hematoma expansion, highlighting the need for very fast treatment in ICH patients.
AB - Objective: To determine the association of ultraearly hematoma growth (uHG) with the CT angiography (CTA) spot sign, hematoma expansion, and clinical outcomes in patients with acute intracerebral hemorrhage (ICH). Methods: We analyzed data from 231 patients enrolled in the multicenter Predicting Haematoma Growth and Outcome in Intracerebral Haemorrhage Using Contrast Bolus CT study. uHG was defined as baseline ICH volume/onset-to-CT time (mL/h). The spot sign was used as marker of active hemorrhage. Outcome parameters included significant hematoma expansion (>33% or >6 mL, primary outcome), rate of hematoma expansion, early neurologic deterioration, 90-day mortality, and poor outcome. Results: uHG was higher in spot sign patients (p < 0.001) and in patients scanned earlier (p < 0.001). Both uHG >4.7 mL/h (p 0.002) and the CTA spot sign (p 0.030) showed effects on rate of hematoma expansion but not its interaction (2-way analysis of variance, p 0.477). uHG >4.7 mL/h improved the sensitivity of the spot sign in the prediction of significant hematoma expansion (73.9% vs 46.4%), early neurologic deterioration (67.6% vs 35.3%), 90-day mortality (81.6% vs 44.9%), and poor outcome (72.8% vs 29.8%), respectively. uHG was independently related to significant hematoma expansion (odds ratio 1.06, 95% confidence interval 1.03-1.10) and clinical outcomes. Conclusions: uHG is a useful predictor of hematoma expansion and poor clinical outcomes in patients with acute ICH. The combination of high uHG and the spot sign is associated with a higher rate of hematoma expansion, highlighting the need for very fast treatment in ICH patients.
UR - http://www.scopus.com/inward/record.url?scp=84980332232&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000002897
DO - 10.1212/WNL.0000000000002897
M3 - Article
C2 - 27343067
AN - SCOPUS:84980332232
SN - 0028-3878
VL - 87
SP - 357
EP - 364
JO - Neurology
JF - Neurology
IS - 4
ER -